story of the week
High-Dose IL-2 in the Era of Targeted Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- The Role of High-Dose Interleukin in RCC
- High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pre-Treated With VEGF-Targeted Therapies
- High-Dose Interleukin-2 Remains Effective Second-Line After Targeted Therapy for Metastatic Renal Cell Carcinoma
- Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma
- Benefits of Immunotherapy for mRCC
Disclosure statements are available on the authors' profiles:
The Journal of Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Role of High Dose Interleukin-2 in the Era of Targeted Therapy
J Urol 2017 Mar 10;[EPub Ahead of Print], J Gills, WP Parker, S Pate, S Niu, P Van Veldhuizen, M Mirza, JM Holzbeierlein, EK LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.